RxDoctor Payments Data

Vijesh Patel, MD

Internal Medicine · Port Neches, TXNPI 1194752196

Payments from drug & device makers

$679in general payments, 2019–2025

Across 35 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$119
  • Johnson & Johnson$90
  • Bayer$75
  • Novartis$67
  • Merck$66
  • Esperion Therapeutics, Inc.$61
  • plus $201 from 9 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$679 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$117,755
Medicare patients
229
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$105,014
EliquisApixaban91$96,330
MounjaroTirzepatide65$71,608
SynjardyEmpagliflozin/Metformin Hcl47$59,925
OzempicSemaglutide41$39,829
XareltoRivaroxaban26$26,780
JardianceEmpagliflozin23$26,733
EntrestoSacubitril/Valsartan13$23,917
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl115$21,514
MyrbetriqMirabegron16$20,752
Xtampza ErOxycodone Myristate11$18,742
SuboxoneBuprenorphine Hcl/Naloxone Hcl33$18,676
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$15,017
Breo ElliptaFluticasone/Vilanterol11$11,666
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$9,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$119$116,68093 claims
PfizerEliquis$30$96,33091 claims
Lilly USA, LLCMounjaro$17$71,60865 claims
Novo NordiskOzempic$13$39,82941 claims
Johnson & JohnsonXarelto$90$26,78026 claims
NovartisEntresto$67$23,91713 claims
Indivior Inc.Suboxone$22$18,67633 claims
AstraZenecaSymbicort$19$2,64612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Port Neches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →